TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Safety of a single dose of Aurexis®
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of a single dose of Aurexis®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically meaningful improvement in LCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response rate of AMG 655 Therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Biochemical Remission of AIH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Six Minute Walking Test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Penile Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior segment parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Occurrence of Chronic Leg Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Packing Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in manually assessed tenderness after 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in manually assessed tenderness after 39 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of acute appendicitis
Endpoint domain: Mortality/survival
Primary endpoint: Number of Reported Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Fecal microbial community composition and structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procalcitonin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Best Corrected Visual Acuity (BCVA) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macular Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Scotomatous Points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Experienced a Grade 3 or Higher Systemic Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Had a Confirmed HIV-1 RNA Greater Than or Equal to 200 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean Snellen BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Risk Taking Behavior
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Myocardial deformation of the LA and LV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite rate of MACCE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in overall cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of patients with mild cognitive impairment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: molecular changes in lung cancer tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Autonomic dysfunction measured by HRV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety measured by questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hemodynamic indexes changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 1-month Adverse Event Occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Total physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Wake up Times
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Correctly identified manikin-simulated heart sounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ctDNA clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma melatonin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With Confirmed Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Patients Achieving Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Achieving Mobilization-adjusted Complete Response (maCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in QTc Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Maximum Change From Baseline in Electrocardiogram (ECG) Morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postpartum vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in IRLS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung clearance index (LCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of subjects experiencing serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with study drug discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Assessment of metformin use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Assessment of insulin use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progression Free Survival 1 (PFS 1)
Endpoint domain: Mortality/survival
Primary endpoint: Sum of Pain Intensity Differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of neurovegetative episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of different populations of dendritic cells and immature cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: DC function based on ability to stimulate antigen specific proliferative and cytolytic T cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Correlation of aflibercept level with host antigen presenting cell phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in overall severity of the clinical picture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological Complete Response (pCR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cumulative usage of morphine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Who Experience an Adverse Events While Using the jDome BikeAround (System)
Endpoint domain: Adverse events/effects
Primary endpoint: Performance Oriented Mobility Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 10-year absolute risk for Cardiovascular Heart Disease
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants with Dose Limiting Toxicity (DLT) in Arm 1
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Dose Limiting Toxicity (DLT) in Arm 2
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Bone Mineral Density (BMD) For Adolescents Assessed by Dual-Energy X-ray Absorptiometry (DXA) Scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Cortisol Level After Adrenocorticotropic Hormone (ACTH) Stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: LH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: FSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Inhibin B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Testicular Size (Volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sperm Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positivity of the new radiotracer Ga-68-NODAGA-MJ9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of coronary artery stenosis more than 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in self-rating of affective reactivity (ARI-S)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical Global Impression - Improvement (CGI-I) total score of 1 or 2
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy of ciprofloxacin XR in treating complicated urinary tract infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of adverse events resulting from multiple biopsies
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Quantitative Myasthenia Gravis (QMG) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to discontinued use of an assistive ambulatory device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differentiation of thyroid cancer from normal and benign tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Optimal dose of Bevacizumab 800CW
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's Depression Rating Scale-Revised (CDRS-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Children's Global Assessment Scale (C-GAS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Somatosensory cortical dynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: decrease in anti-Xa activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Nurses' quality of working life (QoWL)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Mediterranean diet adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Amount of [14C]derived radioactivity in urine and feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of metabolites of asimadoline in plasma, urine, and feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC 0-inf of dalbavancin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of dalbavancin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of dalbavancin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 of dalbavancin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinicians' Treatment Decision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematologic Improvement in Erythroid Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Disability as measured by Pain Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in ODI (Oswestry Disability Index)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Stress level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Postural Sway during Static Stance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dynamic Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in perceived pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Weighted Average Position Score of transit marker capsules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Driver sleepiness
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Macrostructure of sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Reported Engagement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants with DLTs
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma Concentration of Sildenafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall survival within 3 years after surgery
Endpoint domain: Mortality/survival
Primary endpoint: occurrence of postextubation stridor
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast milk excretion of docosahexaenoic acid (DHA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incident rheumatoid arthritis (RA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients decreasing tacrolimus doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication refills
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of cerebrovascular and cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Bowel wall inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bowel wall fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to recover from severe neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Efficacy of PC-ACP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical Site Infection Development
Endpoint domain: Adverse events/effects
Primary endpoint: Conversion rate of nonresectable disease to resectable disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean 48-week Change in DAS28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sustained Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunoprophylaxis failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Average duration of holding the fixation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the iron plasma concentration curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cost-benefit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sustained Virological Response (SVR)-24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of oocytes (COCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Changes in carotid wall volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Microbiological diagnosis of tuberculosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of uncovered stent strut segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety as assessed by orthostatic challenge test
Endpoint domain: Adverse events/effects
Primary endpoint: Safety as assessed by clinical laboratory tests
Endpoint domain: Adverse events/effects
Primary endpoint: Safety as assessed by electrocardiogram (ECG)
Endpoint domain: Adverse events/effects
Primary endpoint: Safety as assessed by Bond and Lader visual analogue scale (VAS)
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma THC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of Irinotecan onkovis needed per treatment cycle
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area Under Concentration from time zero to the last quantifiable (AUC [0-last])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Maximum Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Physical Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readiness for Discharge After Birth
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Aortic Valve Mean Gradient (mm Hg) at Peak Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of appropriate ICD interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Intelligent Quotient
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Motor MDS-UPDRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hemagglutination inhibition (HI) titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pressure Ulcer incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Efficiency of Sperm Aspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Delay time to send a validated exome sequencing report
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: proportion of patients free from MAEs within 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: rate of successful disease treatment at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Superficial electromyography peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline in PWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time at Maximum Plasma Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration (AUC 0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of asymptomatic COVID-19 positive healthcare workers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Myocardial Injury assessed by changes in Troponin values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Patients With FDG-PET Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in CD34+ cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Standard Deviation of Lateral Position (SDLP, cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hyperactive-Impulsive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Executive Functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Duration and severity of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Premature treatment termination
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of PIBF in Endometrial Cancer Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: numbers of patients who develop cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nodule and thyroid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of the cystic part
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thyroid function measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sensitivity and specificity of FLT-PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Correlate SUV with % Ki67 nuclear stain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Voriconazole trough concentrations at steady-state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genotype-specific dosages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of drainage from incisional wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Papilloma Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in motor evoked potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes